Angioedema clinical trials
The registry lists 69 studies for Angioedema across more than 10 countries. 16 are recruiting or about to start. 31 of them are mainly about Angioedema (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09. Counting its narrower condition Angioedemas, Hereditary too: 214 studies, 31 open.
Get an email when these change. Save the Angioedema studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Shire (6) · Astria Therapeutics, Inc. (5) · Pharming Technologies B.V. (5) · Prothya Biosolutions (3) · University Hospital, Grenoble (3) · University Hospital, Lille (3) · Pharvaris Netherlands B.V. (2) · Technical University of Munich (2)
What is being tested here
Drugs under test in Angioedema studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 7, phase 3 first
- Dec 2026A Study of Navenibart in Participants With Hereditary Angioedema · Phase 3 · Astria Therapeutics, Inc.
- Dec 2026Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks · Phase 3 · Octapharma
- Jun 2027Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency · Phase 3 · Pharvaris Netherlands B.V.
- Jan 2027Allergy and Immunology Natural History Study · Columbia University
- Mar 2027ScATtEred Rare Disease Biobanks: a Model of Sample/Data Collection With susTainablE and Shared Criteria · IRCCS Policlinico S. Donato
- Jul 2027Angioedema Biomarker Research Study · Foundation For Rare Disease Research
- Sep 2027Lanadelumab in Long-term Prophylaxis of Acquired Angioedema · Bernstein Clinical Research Center
Who these studies take
Of the 13 Angioedema studies recruiting now, 10 (77%) set no upper age limit and 2 (15%) stop at 75 or younger. 7 (54%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 4 (31%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 5 (38%) | 5 (38%) |
| 18 | 13 (100%) | 13 (100%) |
| 30 | 13 (100%) | 13 (100%) |
| 40 | 13 (100%) | 13 (100%) |
| 50 | 13 (100%) | 13 (100%) |
| 65 | 13 (100%) | 13 (100%) |
| 75 | 13 (100%) | 13 (100%) |
| 85 | 11 (85%) | 11 (85%) |
Across all 69 studies, recruiting or not: 25% stop at 75 or younger and 13% at 65; 39% take children; 0% are for women only and 0% for men only; 16% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 50 of 69. Browse all 69 → or search them.
- Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema AttacksRecruitingNCT06361537Phase 313 countries
- Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor DeficiencyRecruitingNCT07266805Phase 316 countries
- ScATtEred Rare Disease Biobanks: a Model of Sample/Data Collection With susTainablE and Shared CriteriaRecruitingNCT067822301 country
- Angioedema Biomarker Research StudyRecruitingNCT062106981 country
- EAP for Deucrictibant Immediate-releaseAvailableNCT07759141
- A Long-Term Study of Navenibart in Participants With Hereditary AngioedemaEnrolling by invitationNCT07204938Phase 318 countries
- A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients With Hereditary Angioedema (HAE)RecruitingNCT070012805 countries
- Deployment o the Multidisciplinary Prospective Cohort ImminentRecruitingNCT04334031Not applicable1 country
- Allergy and Immunology Natural History StudyRecruitingNCT055844881 country
- SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)RecruitingNCT070214951 country
- Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema PatientsRecruitingNCT07046806Phase 1/21 country
- Armenian NAtionwide REGistry of Systemic Autoimmune and Autoinflammatory DiseasesRecruitingNCT059043011 country
- Lanadelumab in Long-term Prophylaxis of Acquired AngioedemaRecruitingNCT06818474Phase 41 country
- Safety and Efficacy of Conestat Alfa for ACE-Induced AngioedemaNot yet recruitingNCT06679426Phase 3
- Lanadelumab in Bradykinin AngioedemaRecruitingNCT045979441 country
- CLOUD-R HAE REGISTRYRecruitingNCT038459461 country
- A Single-Arm Exploratory Study of NatureU Hista Dissolve on Chronic Urticaria SymptomsCompletedNCT07611032Not applicable1 country
- A Study of Navenibart in Participants With Hereditary AngioedemaActive, not recruitingNCT06842823Phase 324 countries
- A Study of Navenibart (STAR-0215) in Participants With Hereditary AngioedemaCompletedNCT05695248Phase 1/26 countries
- Research of Biomarkers Associated With the Diagnosis and Severity of Bradykinin AngioedemaTerminatedNCT049636341 country
- Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous UrticariaCompletedNCT05936567Phase 23 countries
- Involvement of Monocytic B1 and B2 Receptors in Inflammation and Chronic Vascular Disease in Patients With Hereditary Bradykinetic AngioedemaCompletedNCT04032002Not applicable1 country
- Characterization of Rhythmicity Profiles of Bradykinin-mediated Angioedema Attacks Using a Tracking Smartphone Application.WithdrawnNCT05304091
- A Long-term Study of STAR-0215 in Participants With Hereditary AngioedemaActive, not recruitingNCT06007677Phase 27 countries
- C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) AttacksCompletedNCT0139786413 countries
- A Study to Review the Treatment and Outcomes of Teenagers and Adults With Non-histaminergic Angioedema With Normal C1 Inhibitor in CanadaCompletedNCT055784171 country
- A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-InhibitorCompletedNCT04444895Phase 310 countries
- Mepolizumab in Episodic Angioedema With EosinophiliaTerminatedNCT04128371Phase 21 country
- Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) PatientsCompletedNCT01359969Phase 210 countries
- Treatment of Angiotensin Converting Enzyme Inhibitor-induced AngioedemaTerminatedNCT04679311Phase 21 country
- Evaluation of Tranexamic Acid for Angiotensin-converting Enzyme Inhibitor-induced Angioedema in the Emergency DepartmentCompletedNCT060960771 country
- A Study of STAR-0215 in Healthy Adult ParticipantsCompletedNCT05477160Phase 11 country
- A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)CompletedNCT04206605Phase 310 countries
- Randomized, Double-blind, Two Arms, Multicenter, Phase III Study of Berinert for Treatment of ACE Induced AngioedemaCompletedNCT01843530Phase 31 country
- The Role of Vitamin D in Chronic Urticaria and Angioedema TreatmentCompletedNCT01371877Not applicable1 country
- Vitamin D Levels in Subjects With Chronic Urticaria and AngioedemaCompletedNCT008763691 country
- Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and AdultsNo longer availableNCT045830075 countries
- Treatment of Idiopathic Angioedema With Xolair as Add-on TherapyCompletedNCT02966314Phase 41 country
- Biomarker for Hereditary AngioEdema DiseaseCompletedNCT030297287 countries
- Efficacy and Safety of GNR-038 vs Berinert® in Patients With Hereditary AngioedemaWithdrawnNCT04898309Phase 2/31 country
- Dupilumab in Chronic Spontaneous UrticariaCompletedNCT03749135Phase 21 country
- A Safety Study For Prevenar 13 Among Chinese ChildrenCompletedNCT036569391 country
- Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced AngioedemaTerminatedNCT01343823Phase 21 country
- Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary AngioedemaCompletedNCT00097695Phase 31 country
- Blinded Safety & Efficacy Placebo Controlled Study of Icatibant for Angiotensin Converting Enzyme Inhibitor Induced AngioedemaCompletedNCT01919801Phase 34 countries
- Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese VolunteersCompletedNCT02045264Phase 11 country
- Safety and Pharmacokinetics of GNR-038 in Healthy VolunteersCompletedNCT04557319Phase 11 country
- Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to TherapyCompletedNCT01723072Phase 31 country
- Evaluation of New Markers in Type 3 AngioedemaCompletedNCT03917680Not applicable1 country
- A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic AnaphylaxisCompletedNCT00890162Phase 21 country